Digest Network Come funziona
Network
/
Società
Ni
Non verificato

Nimbus Therapeutics, LLC

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
25/04/2025
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
07/03/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
25/02/2025
Oncologia
Salute
Farmaceutica
Cardiologia
Biotecnologia
Mercato del lavoro
Industria
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
23/10/2024
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
09/10/2024
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0